Professor of Pharmaceutical Sciences,
Ph.D. Boston College, Boston, MA
BA, State University of New York, Oswego
Cardiovascular Targeting, Immunotargeting
Cardiovascular disorders, Tumor targeting, Cell preservation
Novel development of pre-targeted deliver of diagnostic and therapeutic drugs as pro-drug-polymer conjugates by bispecific antibody targeting complexes. This approach allows for exquisitely specific targeting for diagnosis and therapy without the associated adverse outcomes commonly observed with conventional free drug therapies. In addition this approach is amenable to application as a theranostic or companion diagnostic/therapy. Any drug that can be covalently linked to carriers can be applied in the pre-targeting technology and benefit form highly specific targeting as well as reduced off-target toxicities. This pre-targeting technology can be applied to oncology, cardiology and any immune-targeting for diagnositic and therapy.
B.A. Khaw, V.P. Torchilin, I. Vural, J. Narula. Plug and Seal: Prevention of Hypoxic Cardiocyte (1995). Death by Sealing Membrane Lesions with Antimyosin-Liposomes. Nature Medicine 1(11): 1195-1198
J. Narula, N. Haider, R. Virmani, T.G. DiSalvo, F.D. Kolodgie, R.J. Hajjar, U. Schmidt, M.J. Semigran, G.W. Dec, B.A. Khaw. (1996). Programmed myocyte death in end-stage heart failure. N Engl J Med. 335: 1182-1189.
B.A. Khaw, A. Nakazawa, S. O’Donnell, K.Y. Pak, J. Narula. (1997). Avidity of 99mTc-glucarate for the necrotic myocardium: In vivo and in vitro assessment. J Nucl Cardiol. 4: 283-290
140 TF, Room X138